# Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients

> **NCT01374165** · — · WITHDRAWN · sponsor: **Prolong Pharmaceuticals**

## Conditions studied

- Sickle Cell Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01374165
- **Lead sponsor:** Prolong Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-01
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study cancelled.
- **Last updated:** 2018-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01374165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01374165, "Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01374165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*